VivoSeq
Other

Psychiatric Disorder

28

Pipeline Programs↗

6

Active Trials↗

13

Companies Involved↗

Psychiatric Disorder is an emerging landscape with 28 programs across 13 companies. The most active players are Bristol-Myers Squibb, Boehringer Ingelheim, COMPASS Pathways. 8 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

11/100

Mech. Concentration

13/100

Completion Rate

80/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 2N

Neurim Pharmaceuticals Ltd.

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Takeda logo

Takeda

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

26 of 27 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed12 · 57%
Recruiting3 · 14%
Terminated2 · 10%
Not yet recruiting2 · 10%
Withdrawn1 · 5%
Enrolling by invitation1 · 5%

Clinical Trials

Trial Activity

21 trials

A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders
Recruiting·SShanghai Mental Health Center·N/A·NCT07417813·121 enrolled
Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia
Recruiting·—·Phase 2/3·NCT06062953·255 enrolled
Pilot Study on the Acceptability of Auricular Vagus Nerve Neurostimulation for the Prevention of Non-suicidal Self-injury Recurrence in Adolescents
Recruiting·CCentre Hospitalier Régional Metz-Thionville·Preclinical·NCT06433583·22 enrolled
Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.
Not yet recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT05946486·174 enrolled
Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974
Not yet recruiting·YYale University·N/A·NCT07488819·160 enrolled
A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders
Enrolling by invitation·WWuhan University·N/A·NCT05395949·50 enrolled
Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus
Completed·UUniversity Hospital, Clermont-Ferrand·N/A·NCT03125083·40 enrolled
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
Completed·National Institute of Mental Health (NIMH)·Phase 3·NCT00001768·10 enrolled
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Completed·MMateria Medica Holding·Phase 3·NCT04552041·406 enrolled
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
Completed·MMedical University of Vienna·Phase 4·NCT01477203·289 enrolled
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
Completed·Pfizer logoPfizer·Phase 4·NCT01456936·8,144 enrolled
Creatine Treatment in Psychiatric Disorders
Completed·—·Phase 3·NCT00140192·12 enrolled
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
Completed·NNew York State Psychiatric Institute·Phase 1·NCT01519557·68 enrolled
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Completed·Pfizer logoPfizer·Phase 4·NCT01574703·4,595 enrolled
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06853171·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)